TY  - JOUR
AU  - Carmona-Bayonas, Alberto
AU  - Jiménez-Fonseca, Paula
AU  - Lamarca, Ángela
AU  - Barriuso, Jorge
AU  - Castaño, Ángel
AU  - Benavent, Marta
AU  - Alonso, Vicente
AU  - Riesco-Martínez, María Del Carmen
AU  - Alonso-Gordoa, Teresa
AU  - Custodio, Ana
AU  - Sánchez Cánovas, Manuel
AU  - Hernando Cubero, Jorge
AU  - López, Carlos
AU  - Lacasta, Adelaida
AU  - Fernández Montes, Ana
AU  - Marazuela, Mónica
AU  - Crespo, Guillermo
AU  - Escudero, Pilar
AU  - Diaz, José Ángel
AU  - Feliciangeli, Eduardo
AU  - Gallego, Javier
AU  - Llanos, Marta
AU  - Segura, Ángel
AU  - Vilardell, Felip
AU  - Percovich, Juan Carlos
AU  - Grande, Enrique
AU  - Capdevila, Jaume
AU  - Valle, Juan W
AU  - García-Carbonero, Rocio
PY  - 2019
DO  - 10.1200/JCO.19.00980
SN  - 0732-183X
UR  - http://hdl.handle.net/20.500.12105/9162
AB  - PURPOSE: Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is heterogeneous. The aim of the current...
LA  - eng
KW  - PROGNOSTIC-FACTORS
KW  - NEOPLASMS
KW  - EVEROLIMUS
KW  - SUNITINIB
KW  - REGISTRY
KW  - THERAPY
KW  - MODEL
TI  - Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
TY  - journal article
ER  -